Biotech ‘megarounds’ hold steady as startups, VCs wait on IPOs

Biotechnology company funding rounds remain larger than they were in 2022 and 2023, in a sign venture firms continue to favor bigger bets rather than parceling their money into smaller, but more numerous, financings.